Neurocrine Biosciences (NBIX) Expected to Announce Quarterly Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect Neurocrine Biosciences to post earnings of $1.62 per share and revenue of $629.25 million for the quarter.

Neurocrine Biosciences Trading Up 1.7 %

NASDAQ NBIX opened at $150.71 on Wednesday. Neurocrine Biosciences has a 1 year low of $110.95 and a 1 year high of $157.98. The firm has a market capitalization of $15.26 billion, a price-to-earnings ratio of 40.40 and a beta of 0.33. The firm’s 50 day simple moving average is $135.33 and its 200 day simple moving average is $131.30.

Insider Activity

In related news, CEO Kyle Gano sold 65,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the sale, the chief executive officer now owns 135,392 shares in the company, valued at $19,157,968. This represents a 32.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ingrid Delaet sold 272 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total value of $37,563.20. Following the completion of the sale, the insider now owns 2,507 shares of the company’s stock, valued at approximately $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,694 shares of company stock valued at $9,676,730. 4.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NBIX shares. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Royal Bank of Canada decreased their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Raymond James reiterated an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Finally, Piper Sandler restated an “overweight” rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $165.40.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.